News ESC: Study says GLP-1s treat heart failure AND cut emissions Add a beneficial impact on climate change to the long list of benefits being attributed to GLP-1 agonist medicines.
News Nykode changes tack after Roche exits partnership Hit by the loss of a partnership with Roche's Genentech unit last year, Norway's Nykode has narrowed its R&D focus.
News Regeneron preps filings for myasthenia gravis drug Regeneron could be just a few months away from filing for a myasthenia gravis drug that can be dosed just once every three months.
News Diabetics on Lilly's orforglipron shed 10.5% of their weight Eli Lilly has reported the results of a third phase 3 trial of oral weight-loss therapy orforglipron, clearing the way for filings before year-end.
News Rumour partly confirmed as AbbVie acquires Gilgamesh drug Reports of AbbVie's interest in Gilgamesh Pharma were true, as the companies have agreed a $1.2bn acquisition deal for a psychedelic depression drug.
News Argenx poised to expand Vyvgart market off new phase 3 data New data could expand the label of argenx's Vyvgart to include AChR-Ab seronegative patients, ~20% of gMG patients whose current options are limited.
Oncology ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of o... For years, ADCs have been positioned as an important addition to the oncology toolkit. But, could they eventually replace chemotherapy altogether?
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
